
Radius Health RDUS
Quarterly report 2022-Q2
added 08-09-2022
Radius Health Long Term Debt Current 2011-2026 | RDUS
Annual Long Term Debt Current Radius Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 613 K | 2.49 M | 2.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.49 M | 613 K | 1.77 M |
Long Term Debt Current of other stocks in the Drug manufacturers industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aurora Cannabis
ACB
|
5.38 M | $ 3.51 | 1.73 % | $ 86.3 M | ||
|
Alimera Sciences
ALIM
|
634 K | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
4.36 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
5.36 M | - | 7.5 % | $ 6.35 M | ||
|
Canopy Growth Corporation
CGC
|
7.46 M | $ 1.06 | 3.43 % | $ 114 M | ||
|
Agile Therapeutics
AGRX
|
366 K | - | 10.11 % | $ 58.2 M | ||
|
Assertio Holdings
ASRT
|
240 K | $ 12.0 | 1.95 % | $ 76.8 M | ||
|
DURECT Corporation
DRRX
|
1.38 M | - | - | $ 50.1 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
582 K | - | - | $ 2.06 B | ||
|
Eagle Pharmaceuticals
EGRX
|
1.53 M | - | -39.89 % | $ 27.7 M | ||
|
Evolus
EOLS
|
2.53 M | $ 4.92 | -2.48 % | $ 317 M | ||
|
Evoke Pharma
EVOK
|
13.4 K | - | - | $ 36.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
3.91 M | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
914 K | - | 2.45 % | $ 38.1 M | ||
|
Catalent
CTLT
|
13 M | - | - | $ 11.5 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
357 K | $ 3.04 | -0.65 % | $ 42.7 M | ||
|
Jupiter Wellness
JUPW
|
213 K | - | - | $ 33.6 M | ||
|
Athenex
ATNX
|
2.09 M | - | -23.39 % | $ 1.76 M | ||
|
Endo International plc
ENDP
|
956 K | - | - | $ 28.9 M | ||
|
Harrow Health
HROW
|
887 K | $ 34.83 | -0.23 % | $ 1.28 B | ||
|
Emergent BioSolutions
EBS
|
3.5 M | $ 8.15 | -1.98 % | $ 417 M | ||
|
OrganiGram Holdings
OGI
|
1.03 M | $ 1.43 | 0.35 % | $ 402 M | ||
|
Organogenesis Holdings
ORGO
|
4.27 M | $ 2.56 | -0.97 % | $ 337 M | ||
|
Pacira BioSciences
PCRX
|
8.89 M | $ 21.89 | -3.53 % | $ 1.01 B | ||
|
China Pharma Holdings
CPHI
|
39.3 K | $ 0.64 | 3.23 % | $ 11.2 M | ||
|
Sundial Growers
SNDL
|
34.3 M | $ 1.45 | 0.35 % | $ 3.37 M | ||
|
ProPhase Labs
PRPH
|
301 K | - | - | $ 5.07 M | ||
|
TherapeuticsMD
TXMD
|
1.47 M | $ 2.3 | 5.99 % | $ 24 M | ||
|
Lannett Company
LCI
|
2.06 M | - | 1.15 % | $ 7.11 M | ||
|
Veru
VERU
|
1.07 M | $ 2.4 | 1.27 % | $ 324 M | ||
|
Viatris
VTRS
|
80.6 M | $ 13.8 | 2.15 % | $ 16.6 B | ||
|
Perrigo Company plc
PRGO
|
25.7 M | $ 10.19 | 4.84 % | $ 1.41 B | ||
|
Neoleukin Therapeutics
NLTX
|
2.56 M | - | - | $ 193 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
58 K | $ 2.47 | 2.49 % | $ 3.07 M | ||
|
Rockwell Medical
RMTI
|
1.38 M | $ 1.01 | 5.74 % | $ 23.6 M | ||
|
PetIQ
PETQ
|
7.61 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
911 K | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | ||
|
SCYNEXIS
SCYX
|
483 K | $ 0.91 | 0.86 % | $ 45.4 M | ||
|
Recro Pharma
REPH
|
1.1 M | - | -4.76 % | $ 65.3 M | ||
|
Solid Biosciences
SLDB
|
1.79 M | $ 7.81 | 4.41 % | $ 319 M | ||
|
Tilray
TLRY
|
2.47 M | $ 6.9 | -0.07 % | $ 4.26 B | ||
|
Tricida
TCDA
|
2.74 M | - | - | $ 3.25 M | ||
|
cbdMD
YCBD
|
98.7 K | $ 0.76 | 5.29 % | $ 3.28 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
215 K | - | - | $ 55.5 M | ||
|
Zomedica Corp.
ZOM
|
717 K | - | -0.21 % | $ 98 M |